Express News | Revive Therapeutics Ltd - Additional Phase 3 Clinical Trial Data Analyses May Suggest Bucillamine's Potential for Long Covid.

ReutersJun 12 09:06 ET

Express News | Revive Therapeutics Ltd - FDA Has Recommended That Evaluation of Bucillamine for Long Covid Be Submitted as a New Ind Application

ReutersJun 12 09:06 ET

Express News | Revive Therapeutics Ltd - Company Is Exploring Use of Bucillamine as a Potential Treatment for Long Covid

ReutersJun 12 09:06 ET

Express News | Revive Therapeutics Ltd: Would Be Required to Conduct a Clinical Study for De Novo Submission for Possible Approval

ReutersJun 10 07:30 ET

Express News | Revive Therapeutics Ltd: FDA Has Determined That Product Should Follow De Novo Regulatory Pathway

ReutersJun 10 07:30 ET

Express News | Revive Therapeutics Ltd - Meeting Date Assigned by FDA Is June 7, 2024

Moomoo 24/7Apr 18 07:02 ET